| Literature DB >> 8560462 |
Abstract
As an essential metal for cell metabolism, Mg2+ is known to exert antagonism on Ni2+ genotoxic and other effects. This study examined the influence of Mg2+ on Ni(2+)-induced changes in microtubule (MT) assembly in vitro, cytoplasmic MT organization, cellular glutathione (GSH), and cytoskeletal and cytosolic protein sulfhydryls (PSH). As determined by a turbidity assay at 27 degrees C, Ni2+ enhanced the in vitro MT assembly in a Pipes buffer by shortening the initial lag (nucleation phase) and increasing the rate of polymerization with a higher final plateau. However, presence of 1 mM exogenous MgCl2 abolished the Ni2+ enhancing effect. Exposure of 3T3 cells to 2 mM NiCl2 for 20 hr resulted in perinuclear bundling of MTs and decreases in cytoskeletal and cytosolic PSH and cellular GSH levels. However, coincubation of cells with MgCl2 (1.25-20 mM) added to the culture medium markedly diminished the Ni2+ injury to MT organization. Under these conditions the Ni2+ interference with PSH was blocked such that both the cytoskeletal and cytosolic PSH levels returned to the range of control cells without metal treatment. Treatment of cells with Mg2+ (1.25-5 mM) for 20 hr slightly increased, while with higher Mg2+ doses (> 10 mM) decreased, cellular GSH content. Importantly, in Ni(2+)-treated cultures, addition of Mg2+ (1.25-10 mM) elevated GSH levels to > or = 200% of that in cells treated with Ni2+ alone. Furthermore, these Ni2+ and Mg2+ (1.25-10 mM) treated cells actually maintained GSH levels which were essentially unchanged from the basal level of control cells with no metal treatment. Although Mg2+ replacement of Ni2+ bound to MT proteins could be an important mechanism, cellular GSH may also be a critical factor in Mg2+ antagonism on Ni(2+)-enhanced MT assembly in view of the essential role of tubulin PSH in modulating MT assembly and, in turn, the GSH modulation of PSH.Entities:
Mesh:
Substances:
Year: 1996 PMID: 8560462 DOI: 10.1006/taap.1996.0012
Source DB: PubMed Journal: Toxicol Appl Pharmacol ISSN: 0041-008X Impact factor: 4.219